Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

STOK 01.06.2025

Full Press ReleaseSEC FilingsOur STOK Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.08.2025 - Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
  • 01.07.2025 - Zorevunersen Regulatory Alignment & Phase 3 Plans

Recent Filings

  • 01.07.2025 - EX-99.1 EX-99.1
  • 01.07.2025 - 8-K Current report

BEDFORD, Mass.--(BUSINESS WIRE)--Jan. 6, 2025--Stoke Therapeutics, Inc.(Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that its management team will host a webcast and conference call for investors and analysts to discuss successful alignment with global regulatory agencies related to a Phase 3 study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.

The webcast will be conductedTuesday, January 7, 2025at8:00am Eastern Timeand can be accessed from the Investors & News section of Stoke’s website athttps://investor.stoketherapeutics.com/. Research analysts who plan to join the call and participate in the Q&A session may registerhereto receive the dial-in details and a unique PIN. For all others, the listen-only webcast can be accessed by clickinghere. A replay of the webcast will be archived and available for at least 90 days following the event.

AboutStoke Therapeutics

Stoke Therapeutics(Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke’s first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered inBedford, Massachusettswith offices inCambridge, Massachusetts. For more information, visithttps://www.stoketherapeutics.com/.

About Zorevunersen

Zorevunersen is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials. Stoke believes that zorevunersen, a proprietary antisense oligonucleotide (ASO), has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome. Zorevunersen is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of theSCN1Agene to restore physiological NaV1.1 levels, thereby reducing both occurrence of seizures and significant non-seizure comorbidities. Zorevunersen has been granted orphan drug designation by the FDA and the EMA. The FDA has also granted zorevunersen rare pediatric disease designation and Breakthrough Therapy Designation for the treatment of Dravet syndrome with a confirmed mutation, not associated with gain-of-function, in theSCN1Agene.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20250106021231/en/

Stoke Media & Investor Contacts:Dawn KalmarChief Communications Officerdkalmar@stoketherapeutics.com781-303-8302Doug SnowDirector, Communications & Investor RelationsIR@stoketherapeutics.com508-642-6485

Source:Stoke Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com